Category: Network News

GlycoNet partner company, Alectos Therapeutics, enters ground-breaking $700 million agreement with Biogen

GlycoNet partner company, Alectos Therapeutics, enters ground-breaking $700 million agreement with Biogen

This collaboration combines Alectos’ expertise in small-molecule therapeutics with Biogen’s development capabilities in movement disorders.

Molecules with anti-inflammatory, restorative properties could be key to tackling neurodegenerative disease

Molecules with anti-inflammatory, restorative properties could be key to tackling neurodegenerative disease

GlycoNet researchers are studying a group of molecules that could provide insight into treating and monitoring neurodegenerative diseases.

GlycoNet investigator presents game-changing glycomics research to the Parliamentary Health Research Caucus

GlycoNet investigator presents game-changing glycomics research to the Parliamentary Health Research Caucus

Dr. Lori Burrows shared how glycomics research is being used to develop a more effective vaccine against turberculosis.

New educational resources bolster vaccine confidence, information literacy

New educational resources bolster vaccine confidence, information literacy

GlycoNet received a NSERC PromoScience grant and partnered with the Centre for Mathematics, Science and Technology Education to develop resources that educators can use to teach the science behind vaccines and engage students in critical thinking.

New treatment could reduce tissue damage in Duchenne muscular dystrophy patients by as much as 50 per cent

New treatment could reduce tissue damage in Duchenne muscular dystrophy patients by as much as 50 per cent

A carbohydrate-derived drug shows promise as a treatment to slow progression of the most common form of muscular dystrophy.

en_USEnglish
Scroll to Top